Jennerex Biotherapeutics Inc., of San Francisco, and Transgene SA, of Strasbourg, France, said enrollment in the 120-patient TRAVERSE Phase IIb study testing Pexa-Vec (JX-594/TG6006, pexastimogene devacirepvec) for the treatment of advanced primary liver cancer in patients who failed prior therapy with Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer Ag) is complete

PharmaMar SA, of Madrid, a subsidiary of Zeltia SA, said it completed enrollment in its Phase IIb study testing PM01183 vs

Baxter International Inc., of Deerfield, Ill., said a Phase III study testing immunoglobulin did not meet the co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease

Transition Therapeutics Inc., of Toronto, reported results of a five-week proof-of-concept study testing TT-401 in Type II diabetic and obese nondiabetic subjects, showing that once-weekly treatment demonstrated significant improvements in glycemic control and reductions in body weight...Versartis Inc., of Redwood City, Calif., said positive results from its first Phase I study testing VRS-317, a long-acting form of recombinant human growth hormone, in growth hormone-deficient (GHD) adults are

Northwest Biotherapeutics Inc., of Bethesda, Md., said its Phase III study testing DCVax personalized immune therapy in glioblastoma multiforme was "adopted" as a national priority trial in the UK

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair

The trial is a randomized, multicenter, open-label study testing ibrutinib (PCI-32765) in patients 65 years or older with treatment-naïve CLL/SLL

Cellular Biomedicine Group, of Palo Alto, Calif., has started a Phase I study testing its HaMPC (human adipose-derived mesenchymal progenitor cells) therapy for knee osteoarthritis...Novavax Inc., of Rockville, Md., said top-line data from its Phase II dose-ranging study testing its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age hit its protocol-specified objectives, supporting progression to the next stage of advanced clinical testing

NewLink Genetics Corp., of Ames, Iowa, said it started a Phase II study testing its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer

Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said the independent data monitoring committee recommended that the company continue as planned its pivotal Phase III study testing Firdapse for the treatment of Lambert-Easton myasthenic syndrome (LEMS), a rare autoimmune disorder characterized by muscle weakness of the limbs

Alder Biopharmaceuticals Inc., of Bothell, Wash., said it dosed the first patients in its Phase II study testing antibody therapeutic candidate ALD403, which targets calcitonin gene-related peptide for migraine

Biothera Inc., of Eagen, Minn., said it completed enrollment of its 90-patient Phase IIb study testing Imprime PGG, Avastin (bevacizumab, Roche AG) and two chemotherapeutic drugs in non-small-cell lung cancer

Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase II study testing protein therapeutic ACE-536, in patients with beta-thalassemia

AcelRx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data demonstrating that the first of two pivotal Phase III studies testing its sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System met its primary endpoint, which evaluated pain intensity over the 48-hour study period compared to baseline, or Summed Pain Intensity Difference (SPID-48), in patients following major open abdominal surgery

CytRx Corp., of Los Angeles, said it completed enrollment of 140 patients in its Phase IIb study testing oral retinoid compound tamibarotene in combination with chemotherapeutic agents as a first-line treatment in advanced non-small-cell lung cancer

Inviragen Inc., of Fort Collins, Colo., said it started the second stage of its ongoing Phase II study testing DENVax, its dengue vaccine, following review and recommendation by the data safety monitoring board

Kiadis Pharma BV, of Amsterdam, the Netherlands, said it received a No Objection Letter from Canadian regulators to proceed with a Phase II study testing ATIR, a cell-based product designed to enable stem cell transplantation from mismatched family donors

C3 Jian Inc., of Los Angeles, said it completed enrollment in a Phase I study testing C16G2, a synthetic peptide derived from its pheromone signaling platform technology called STAMPS (Specifically Targeted Antimicrobial Peptides...Peregrine Pharmaceuticals Inc., of Tustin, Calif., said updated data from its Phase II study testing bavituximab in patients with second-line non-small-cell lung cancer showed a meaningful improvement in median overall survival of 11 .7 months in the 3-mg/kg-bavituximab

Ltd., of Seoul, South Korea, said it filed an investigational new drug application with Korean regulators to start Phase II and Phase III studies testing its RNL-Astrostem stem cell drug in patients with cerebral palsy